Lipid Management with Statin Therapy

Patient Selection and Dosing

• For patients taking cyclosporine, tacrolimus, everolimus, or sirolimus, the maximum dose of rosuvastatin should be limited to 5 mg daily due to severe drug interactions, which can increase rosuvastatin exposure 7-fold, as recommended by the American College of Cardiology 1, 2, 3
• The recommended starting dose of rosuvastatin is 10-20 mg daily, with dosage individualized based on cardiovascular risk factors, LDL-C levels, and treatment goals 4

Dose Adjustment and Monitoring

• For high-risk patients requiring more than 50% LDL-C reduction, consider starting with or titrating to 20-40 mg daily, with high-intensity therapy achieving ≥50% LDL-C reduction, as recommended by the American College of Cardiology 1, 2, 5, 6
• No dosage adjustment is needed for mild to moderate renal impairment, but for severe renal impairment (CrCl <30 mL/min/1.73 m²), the starting dose should be 5 mg daily and the maximum dose should be 10 mg daily 4, 7

Efficacy and Safety

• Rosuvastatin demonstrates greater LDL-C reduction compared to other statins at equivalent doses, with 10 mg rosuvastatin reducing LDL-C by approximately 49%, which is significantly more effective than pravastatin 20 mg and simvastatin 20 mg, as reported by the American College of Cardiology 1, 2
• Pravastatin is classified as a moderate-intensity statin and may not achieve adequate LDL-C reduction in all high-risk patients, necessitating consideration of more potent statins, as recommended by the American Heart Association 8

Intensity Levels and Dosage

• The following intensity levels and corresponding rosuvastatin doses are recommended:

1, 2, 4, 5

• For patients requiring high-intensity statin therapy (>50% LDL-C reduction), an alternative statin may be needed, as pravastatin at 80 mg daily may not achieve this level of reduction, according to the American College of Cardiology 8

Special Considerations

• Dosage modifications are necessary with certain concomitant medications, including cyclosporine, darolutamide, gemfibrozil, and various antiviral medications, to minimize the risk of adverse effects, as recommended by clinical guidelines 4
• For elderly patients (>75 years), the standard dose of pravastatin (40 mg) is generally more effective than a low dose for cardiovascular event prevention, and statin therapy should be continued if already initiated, as suggested by the American Heart Association 8

Overdose Management

• Overdose manifestations typically involve muscle-related toxicity, laboratory abnormalities, and other symptoms, with rhabdomyolysis being the most serious, as reported in Circulation 3
• Management of overdose involves discontinuing rosuvastatin immediately, providing supportive care, and monitoring renal function closely, as recommended by clinical guidelines 3